Skip to main content

Advertisement

Log in

Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Background

Mycophenolic acid (MPA), the active compound of mycophenolate mofetil (MMF), is widely used in lupus nephritis treatment. Therapeutic drug monitoring of adults suggests that area under the concentration-time curve (AUC) of MPA (MPA-AUC) is associated with clinical outcomes, but childhood data are scarce.

Methods

Retrospective study of 27 children with biopsy-proven lupus nephritis treated with MMF between 2008 and 2016. In 25 children, MPA-AUC was performed within 6 months after kidney biopsy and MMF initiation. Treatment response at 6 months was defined as normal or improved GFR by 25% compared with baseline, 50% reduction of proteinuria to < 0.5 g/day or 50 mg/mmol, and no hematuria.

Results

A total of 62 MPA-AUC were analyzed in 27 patients. Overall median was 44 mg h/L (interquartile range [IQR] 33–54). Individual dose adaptation was required in 32 cases (52%) to achieve target AUC of 30–60 mg h/L. At 6 months, 14/25 patients were defined as responders (56%, median MPA-AUC 49 mg h/L (40–59)) and 11/25 as non-responders (44%, 29 mg h/L (24–38)). Patients with MPA-AUC levels > 45, 30–45, and < 30 mg h/L had 6-month response rates of 89% (8/9), 60% (6/10), and 0% (0/6), respectively. In a logistic regression model adjusted for age, sex, lupus nephritis classification, and time since MMF initiation, an MPA-AUC > 45 mg h/L was significantly associated with therapeutic response (OR 3.6, 95% CI 2.4–9.5, p = 0.03).

Conclusions

Therapeutic drug monitoring leading to individualized dosing may improve efficacy of MMF. MPA-AUC > 45 mg h/L is associated with better response rate and may be considered as a target value in pediatric lupus nephritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Pineles D, Valente A, Warren B, Peterson MG, Lehman TJ, Moorthy LN (2011) Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. Lupus 20:1187–1192

    Article  CAS  Google Scholar 

  2. Bader-Meunier B, Armengaud JB, Haddad E, Salomon R, Deschênes G, Koné-Paut I, Leblanc T, Loirat C, Niaudet P, Piette JC, Prieur AM, Quartier P, Bouissou F, Foulard M, Leverger G, Lemelle I, Pilet P, Rodière M, Sirvent N, Cochat P (2005) Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J Pediatr 146:648–653

    Article  CAS  Google Scholar 

  3. Ambrose N, Morgan TA, Galloway J, Ionnoau Y, Beresford MW, Isenberg DA, UK JSLE Study Group (2016) Differences in disease phenotype and severity in SLE across age groups. Lupus 25:1542–1550

    Article  CAS  Google Scholar 

  4. Son MB, Johnson VM, Hersh AO, Lo MS, Costenbader KH (2014) Outcomes in hospitalized pediatric patients with systemic lupus erythematosus. Pediatrics 133:e106–e113

    Article  Google Scholar 

  5. Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED (2008) Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 58:556–562

    Article  Google Scholar 

  6. Livingston B, Bonner A, Pope J (2011) Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus 20:1345–1355

    Article  CAS  Google Scholar 

  7. Henderson LK, Masson P, Craig JC, Roberts MA, Flanc RS, Strippoli GF, Webster AC (2013) Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 61:74–87

    Article  Google Scholar 

  8. Palmer SC, Tunnicliffe DJ, Singh-Grewal D, Mavridis D, Tonelli M, Johnson DW, Craig JC, Tong A, Strippoli GFM (2017) Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials. Am J Kidney Dis 70:324–336

    Article  Google Scholar 

  9. Falcini F, Capannini S, Martini G, La Torre F, Vitale A, Mangiantini F, Nacci F, Cerinic MM, Cimaz R, Zulian F (2009) Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicenter study. Lupus 18:139–143

    Article  CAS  Google Scholar 

  10. Kazyra I, Pilkington C, Marks SD, Tullus K (2010) Mycophenolate mofetil treatment in children and adolescents with lupus. Arch Dis Child 95:1059–1061

    Article  Google Scholar 

  11. Pereira T, Abitbol CL, Seeherunvong W, Katsoufis C, Chandar J, Freundlich M, Zilleruelo G (2011) Three decades of progress in treating childhood-onset lupus nephritis. Clin J Am Soc Nephrol 6:2192–2199

    Article  CAS  Google Scholar 

  12. Hara R, Miyazawa H, Nishimura K, Momoi T, Nozawa T, Kikuchi M, Sakurai N, Kizawa T, Shimamura S, Yasuda S, Hiromura K, Sada KE, Kawaguchi Y, Tamura N, Takei S, Takasaki Y, Atsumi T, Mori M (2015) A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan. Mod Rheumatol 25:858–864

    PubMed  Google Scholar 

  13. Smith E, Al-Abadi E, Armon K, Bailey K, Ciurtin C, Davidson J, Gardner-Medwin J, Haslam K, Hawley D, Leahy A, Leone V, McErlane F, Mewar D, Modgil G, Moots R, Pilkington C, Ramanan A, Rangaraj S, Riley P, Sridhar A, Wilkinson N, Beresford MW, Hedrich CM (2019) Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus 28:613–620

    Article  CAS  Google Scholar 

  14. Tian SY, Silverman ED, Pullenayegum E, Brown PE, Beyene J, Feldman BM (2017) Comparative effectiveness of mycophenolate mofetil for the treatment of juvenile-onset proliferative lupus nephritis. Arthritis Care Res (Hoboken) 69:1887–1894

    Article  CAS  Google Scholar 

  15. Hogan J, Godron A, Baudouin V, Kwon T, Harambat J, Deschênes G, Niel O (2018) Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. Pediatr Nephrol 33:111–116

    Article  Google Scholar 

  16. Groot N, de Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P, McCann L, Özen S, Pilkington CA, Ravelli A, Royen-Kerkhof AV, Uziel Y, Vastert BJ, Wulffraat NM, Beresford MW, Kamphuis S (2017) European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis 76:1965–1973

    Article  CAS  Google Scholar 

  17. Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, Marquet P, Kuypers DR, van Gelder T, Cattaneo D (2011) Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev (Orlando) 25:47–57

    Article  Google Scholar 

  18. Zahr N, Amoura Z, Debord J, Hulot JS, Saint-Marcoux F, Marquet P, Piette JC, Lechat P (2008) Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. Clin Pharmacokinet 47:277–284

    Article  CAS  Google Scholar 

  19. Lertdumrongluk P, Somparn P, Kittanamongkolchai W, Traitanon O, Vadcharavivad S, Avihingsanon Y (2010) Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int 78:389–395

    Article  CAS  Google Scholar 

  20. Alexander S, Fleming DH, Mathew BS, Varughese S, Jeyaseelan V, Tamilarasi V, Jacob CK, John GT (2014) Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study. Ther Drug Monit 36:423–432

    Article  CAS  Google Scholar 

  21. Zabotti A, Baraldo M, Quartuccio L, Sacco S, De Marchi G, De Vita S (2015) Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring. Clin Rheumatol 34:171–174

    Article  CAS  Google Scholar 

  22. Abd Rahman AN, Tett SE, Abdul Gafor HA, McWhinney BC, Staatz CE (2015) Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis. Br J Clin Pharmacol 80:1064–1075

    Article  CAS  Google Scholar 

  23. Woillard JB, Bader-Meunier B, Salomon R, Ranchin B, Decramer S, Fischbach M, Berard E, Guigonis V, Harambat J, Dunand O, Tenenbaum J, Marquet P, Saint-Marcoux F (2014) Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring. Br J Clin Pharmacol 78:867–876

    Article  CAS  Google Scholar 

  24. Sherwin CM, Sagcal-Gironella AC, Fukuda T, Brunner HI, Vinks AA (2012) Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Br J Clin Pharmacol 73:727–740

    Article  CAS  Google Scholar 

  25. Sagcal-Gironella AC, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, Sherwin CM, Klein-Gitelman MS, Vinks AA, Brunner HI (2011) Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum 40:307–313

    Article  CAS  Google Scholar 

  26. Hui-Yuen JS, Tran T, Taylor J, Truong K, Li X, Bermudez LM, Starr AJ, Eichenfield AH, Imundo LF, Askanase AD (2016) Use of glucuronidated mycophenolic acid levels for therapeutic monitoring in pediatric lupus nephritis patients. J Clin Rheumatol 22:75–79

    Article  Google Scholar 

  27. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    Article  CAS  Google Scholar 

  28. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    Article  CAS  Google Scholar 

  29. Haute Autorité de Santé (2010). Lupus Systémique. Protocole National de Diagnostic et de Soins. Accessed at https://www.has-sante.fr/jcms/c_2751894/fr/lupus-systemique

  30. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15:241–250

    Article  Google Scholar 

  31. Neumann I, Fuhrmann H, Fang IF, Jaeger A, Bayer P, Kovarik J (2008) Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrol Dial Transplant 23:3514–3520

    Article  CAS  Google Scholar 

  32. Pourafshar N, Karimi A, Wen X, Sobel E, Pourafshar S, Agrawal N, Segal E, Mohandas R, Segal MS (2019) The utility of trough mycophenolic acid levels for the management of lupus nephritis. Nephrol Dial Transplant 34:83–89

    Article  CAS  Google Scholar 

  33. Kuypers DR, Le Meur Y, Cantarovich M, Tredger MJ, Tett SE, Cattaneo D, Tonshoff B, Holt DW, Chapman J, Gelder T (2010) Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 5:341–358

    Article  CAS  Google Scholar 

  34. Saint-Marcoux F, Vandierdonck S, Premaud A, Debord J, Rousseau A, Marquet P (2011) Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients. Ther Drug Monit 33:285–294

    Article  Google Scholar 

  35. Staatz CE, Tett SE (2007) Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 46:13–58

    Article  CAS  Google Scholar 

  36. Tellier S, Dallocchio A, Guigonis V, Saint-Marcoux F, Llanas B, Ichay L, Bandin F, Godron A, Morin D, Brochard K, Gandia P, Bouchet S, Marquet P, Decramer S, Harambat J (2016) Mycophenolic acid pharmacokinetics and relapse in children with steroid-dependent idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 11:1777–1782

    Article  CAS  Google Scholar 

  37. Van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T (2006) Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 17:871–880

    Article  Google Scholar 

  38. Hackl A, Cseprekal O, Gessner M, Liebau MC, Habbig S, Ehren R, Müller C, Taylan C, Dötsch J, Weber LT (2016) Mycophenolate mofetil therapy in children with idiopathic nephrotic syndrome: does therapeutic drug monitoring make a difference. Ther Drug Monit 38:274–279

    Article  CAS  Google Scholar 

  39. Hackl A, Becker JU, Körner LM, Ehren R, Habbig S, Nüsken E, Nüsken KD, Ebner K, Liebau MC, Müller C, Pohl M, Weber LT (2018) Mycophenolate mofetil following glucocorticoid treatment in Henoch-Schönlein purpura nephritis: the role of early initiation and therapeutic drug monitoring. Pediatr Nephrol 33:619–629

    Article  Google Scholar 

  40. Fukuda T, Goebel J, Thøgersen H, Maseck D, Cox S, Logan B, Sherbotie J, Seikaly M, Vinks AA (2011) Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. J Clin Pharmacol 51:309–320

    Article  CAS  Google Scholar 

  41. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157–1167

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jérôme Harambat.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Godron-Dubrasquet, A., Woillard, JB., Decramer, S. et al. Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis. Pediatr Nephrol 36, 341–347 (2021). https://doi.org/10.1007/s00467-020-04733-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-020-04733-x

Keywords

Navigation